A Randomized, Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Subcutaneously and Intravenously Delivered Anifrolumab in Healthy Chinese Participants
Latest Information Update: 31 Oct 2024
At a glance
- Drugs Anifrolumab (Primary) ; Anifrolumab (Primary)
- Indications Cutaneous lupus erythematosus; Lupus nephritis; Myositis; Scleroderma; Sjogren's syndrome; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 31 Oct 2024 New trial record